The sooner the better: Genetic testing following ovarian cancer diagnosis

• Published in: Gynecologic oncology Vol. 137; no. 3; pp. 423 - 429
• Main Authors: Fox, E, McCuaig, J, Demsky, R, Shuman, C, Chitayat, D, Maganti, M, Murphy, J, Rosen, B, Ferguson, S, Randall Armel, S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2015
• Subjects: Adult; Aged; Aged, 80 and over; BRCA1; BRCA2; Cystadenocarcinoma, Serous - diagnosis; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - pathology; Family Health; Female; Genes, BRCA1; Genes, BRCA2; Genetic counseling; Genetic Counseling - methods; Genetic testing; Genetic Testing - methods; Germ-Line Mutation; Hematology, Oncology and Palliative Medicine; Humans; Middle Aged; Neoplasm Grading; Obstetrics and Gynecology; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Serous ovarian cancer; Serous ovarian cancer; Genetic counseling; BRCA1; Genetic testing; BRCA2
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2015.03.057

Abstract Objective As treatment based genetic testing becomes a reality, it is important to assess the attitudes and preferences of women newly diagnosed with ovarian cancer regarding genetic testing. The objective of this study was to determine when women with a diagnosis of high grade serous ovarian cancer would prefer to undergo genetic testing and factors that influence this preference. Methods Women over 18 years of age with a known diagnosis of high grade serous ovarian cancer diagnosed between October 2010–2013 were identified via the Princess Margaret Cancer Center Registry. Participants completed a questionnaire, which obtained preferences and attitudes towards genetic testing, cancer history, and demographic information. Results 120 of the 355 women identified (33.8%) completed the questionnaires. The median age at time of ovarian cancer diagnosis was 57 years (range 35–84). The majority of participants in this study were offered (94.6%) and pursued (84.8%) genetic testing. In this cohort, testing was most frequently offered at diagnosis (41.8%) or during treatment (19.1%). In this study, women with high grade serous ovarian cancer felt that genetic testing should be offered before or at the time of diagnosis (67.8%). Having a family history of breast or ovarian cancer was significantly (p = 0.012) associated with preferring genetic testing at an earlier time point in the disease course. Conclusions Our results demonstrate that women with high grade serous ovarian cancer acknowledge the personal and clinical utility of genetic testing and support test implementation at the time of cancer diagnosis.